We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medifast Q3 Earnings on the Horizon: Key Insights for Investors
Read MoreHide Full Article
Key Takeaways
MED's Q3 revenues are expected to fall 23.9% to $68 million, with a projected loss of 40 cents per share.
Growing GLP-1 adoption and a shrinking active coach base likely pressured MED's sales and client acquisition.
MED's better client retention, coach training and Catalyst cost-saving efforts might have eased Q3 pressures.
Medifast, Inc. (MED - Free Report) prepares to unveil its third-quarter fiscal 2026 results on Oct. 26, before market open. Investors are eager to see if the company can beat market expectations.
The Zacks Consensus Estimate for revenues is pegged at $68 million, implying a 23.9% decline from the prior year. Meanwhile, the consensus mark for earnings has been unchanged at a loss of 40 cents per share in the past seven days. This indicates a substantial decline from the year-ago period’s loss of 21 cents per share. MED has a trailing four-quarter negative earnings surprise of 462.2%, on average.
Medifast is likely to have faced challenges from the growing adoption of GLP-1 medications, which have been reshaping demand across the traditional weight-loss market. The company has previously highlighted that this shift has been affecting client acquisition and coach participation. These industry dynamics, along with continued competition in the weight-management category, might have remained meaningful headwinds in the to-be-reported quarter.
The continued decline in Medifast's active earning coach base might have pressured quarterly revenues. The company has previously indicated that coach numbers are likely to remain under pressure despite improvements in productivity. A smaller coach network might have limited customer reach and sales opportunities, partly offsetting benefits from higher revenue per coach. These factors are likely to have constrained overall business performance in the third quarter.
Profitability is also likely to have remained under pressure due to lower sales volumes and reduced leverage on fixed operating costs. The company has previously noted that declining revenues might have affected its ability to absorb fixed expenses, resulting in gross margin pressure. These factors might have continued to weigh on earnings performance in the quarter, despite ongoing efforts to streamline operations and control expenses.
However, Medifast's strategic initiatives are likely to have provided some support during the quarter. The rollout of its Trilivy brand and new Reset Fuelings, alongside an enhanced coach compensation structure and training platform, might have supported coach engagement and productivity. Meanwhile, improving client retention trends and the company's Catalyst cost-saving program, focused on facility rationalization and AI-related efficiencies, might have helped mitigate some operating pressures.
What the Zacks Model Says About MED
Our proven model doesn’t conclusively predict an earnings beat for Medifast this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
Medifast currently has a Zacks Rank #1 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With the Favorable Combination
Here are a few companies worth considering, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
The Zacks Consensus Estimate for Sysco’s upcoming quarter’s earnings per share is pegged at $1.16, which implies a 0.9% increase year over year. The consensus estimate for Sysco’s quarterly revenues is pegged at $22.19 billion, which indicates a surge of 4.9% from the figure reported in the prior-year quarter. SYY delivered a trailing four-quarter earnings surprise of around 1%, on average.
Freshpet, Inc. (FRPT - Free Report) currently has an Earnings ESP of +1.41% and a Zacks Rank of 3. The Zacks Consensus Estimate for Freshpet’s upcoming quarter’s EPS is pegged at 36 cents, implying a 21.7% decrease from the year-ago period.
The consensus mark for Freshpet’s quarterly revenues is pegged at $309.2 million, which indicates an increase of 7% from the prior-year quarter. FRPT delivered a trailing four-quarter earnings surprise of 21.9%, on average.
The Hershey Company (HSY - Free Report) currently has an Earnings ESP of +0.30% and a Zacks Rank of 3. The Zacks Consensus Estimate for Hershey’s upcoming quarter’s EPS is pegged at $2.12 per share, which implies a 63.1% increase year over year.
The consensus estimate for Hershey’s quarterly revenues is pegged at $3.25 billion, which calls for 2.3% growth from the figure reported in the prior-year quarter. HSY delivered a trailing four-quarter earnings surprise of 21.8%, on average.
View the Zacks #1 Rank List
Image: Bigstock
Medifast Q3 Earnings on the Horizon: Key Insights for Investors
Key Takeaways
Medifast, Inc. (MED - Free Report) prepares to unveil its third-quarter fiscal 2026 results on Oct. 26, before market open. Investors are eager to see if the company can beat market expectations.
The Zacks Consensus Estimate for revenues is pegged at $68 million, implying a 23.9% decline from the prior year. Meanwhile, the consensus mark for earnings has been unchanged at a loss of 40 cents per share in the past seven days. This indicates a substantial decline from the year-ago period’s loss of 21 cents per share. MED has a trailing four-quarter negative earnings surprise of 462.2%, on average.
MEDIFAST INC Price, Consensus and EPS Surprise
MEDIFAST INC price-consensus-eps-surprise-chart | MEDIFAST INC Quote
Key Factors to Note for MED's Q3 Earnings
Medifast is likely to have faced challenges from the growing adoption of GLP-1 medications, which have been reshaping demand across the traditional weight-loss market. The company has previously highlighted that this shift has been affecting client acquisition and coach participation. These industry dynamics, along with continued competition in the weight-management category, might have remained meaningful headwinds in the to-be-reported quarter.
The continued decline in Medifast's active earning coach base might have pressured quarterly revenues. The company has previously indicated that coach numbers are likely to remain under pressure despite improvements in productivity. A smaller coach network might have limited customer reach and sales opportunities, partly offsetting benefits from higher revenue per coach. These factors are likely to have constrained overall business performance in the third quarter.
Profitability is also likely to have remained under pressure due to lower sales volumes and reduced leverage on fixed operating costs. The company has previously noted that declining revenues might have affected its ability to absorb fixed expenses, resulting in gross margin pressure. These factors might have continued to weigh on earnings performance in the quarter, despite ongoing efforts to streamline operations and control expenses.
However, Medifast's strategic initiatives are likely to have provided some support during the quarter. The rollout of its Trilivy brand and new Reset Fuelings, alongside an enhanced coach compensation structure and training platform, might have supported coach engagement and productivity. Meanwhile, improving client retention trends and the company's Catalyst cost-saving program, focused on facility rationalization and AI-related efficiencies, might have helped mitigate some operating pressures.
What the Zacks Model Says About MED
Our proven model doesn’t conclusively predict an earnings beat for Medifast this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
Medifast currently has a Zacks Rank #1 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With the Favorable Combination
Here are a few companies worth considering, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Sysco Corporation (SYY - Free Report) currently has an Earnings ESP of +2.58% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Sysco’s upcoming quarter’s earnings per share is pegged at $1.16, which implies a 0.9% increase year over year. The consensus estimate for Sysco’s quarterly revenues is pegged at $22.19 billion, which indicates a surge of 4.9% from the figure reported in the prior-year quarter. SYY delivered a trailing four-quarter earnings surprise of around 1%, on average.
Freshpet, Inc. (FRPT - Free Report) currently has an Earnings ESP of +1.41% and a Zacks Rank of 3. The Zacks Consensus Estimate for Freshpet’s upcoming quarter’s EPS is pegged at 36 cents, implying a 21.7% decrease from the year-ago period.
The consensus mark for Freshpet’s quarterly revenues is pegged at $309.2 million, which indicates an increase of 7% from the prior-year quarter. FRPT delivered a trailing four-quarter earnings surprise of 21.9%, on average.
The Hershey Company (HSY - Free Report) currently has an Earnings ESP of +0.30% and a Zacks Rank of 3. The Zacks Consensus Estimate for Hershey’s upcoming quarter’s EPS is pegged at $2.12 per share, which implies a 63.1% increase year over year.
The consensus estimate for Hershey’s quarterly revenues is pegged at $3.25 billion, which calls for 2.3% growth from the figure reported in the prior-year quarter. HSY delivered a trailing four-quarter earnings surprise of 21.8%, on average.